The global stem cell therapy market size was exhibited at USD 10.51 billion in 2022 and is expected to hold around USD 18.7 billion by 2030, growing at a CAGR of 7.47% from 2022 to 2030.
The global stem cell therapy market size was exhibited at USD 10.51 billion in 2022 and is expected to hold around USD 18.7 billion by 2030, growing at a CAGR of 7.47% from 2022 to 2030.
Within the body, stem cells have an amazing capacity for self-renewal. Because they can differentiate into specific cell types of tissue or organ, stem cells can be present in the human body at both early and adult stages of life.
Due to its extraordinary ability to split and reproduce itself time and time again, stem cell treatment research has received enormous funding for more than 50 years. Furthermore, because of their lack of specialization, they can develop into a wide range of tissue types, making them useful in regenerative medicine. Additionally, a whole new organ can be created using embryonic stem cells. The majority of stem cell therapies are still in the research stage.
Get the Sample Copy of This Report@ https://www.precedenceresearch.com/sample/1989
Market Growth
The availability of stem cell therapies and ongoing public awareness of this fact has increased the demand for system development and innovation. In order to enhance their research and development efforts, the majority of market participants are focusing on building partnerships. These partnerships may assist to increase the market for stem cell treatments in both emerging and developed countries in the years to come. More money has been allocated to cell-based research, which is now being done at a faster rate. A developing market exists for induced pluripotent stem cells, which are obtained by genetically reprogramming adult human body stem cells in order to obtain embryonic-stage stem cells. It works out to be a superb substitute for the embryonic stem cells now on the market.
Stem Cell Therapy Market Report Scope
|
Report Coverage |
Details |
|
Market Size In 2022 |
USD 10.51 Billion |
|
Market Size By 2030 |
USD 18.7 Billion |
|
Growth Rate From 2022 to 2030 |
CAGR of 7.47% |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
By Product, By Therapy Type, By Application, By Technology, By End User |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Regional Analysis
The availability of stem cell therapies and ongoing public awareness of this fact has increased the demand for system development and innovation. In order to enhance their research and development efforts, the majority of market participants are focusing on building partnerships. These partnerships may assist to increase the market for stem cell treatments in both emerging and developed countries in the years to come. More money has been allocated to cell-based research, which is now being done at a faster rate. A developing market exists for induced pluripotent stem cells, which are obtained by genetically reprogramming adult human body stem cells in order to obtain embryonic-stage stem cells. It works out to be a superb substitute for the embryonic stem cells now on the market. The Asia Pacific region is anticipated to experience strong growth in the upcoming years, with the highest predicted compound annual growth rate of 9.2%.
Ask Here for Customization@ https://www.precedenceresearch.com/customization/1989
Market Dynamics
Drivers
The market for stem cell therapy is expected to develop as the prevalence of uncommon genetic illnesses rises. Millions of people worldwide experience rare diseases including thalassemia, phenylketonuria, cystic fibrosis, and others every year. For instance, the Firstpost analysis estimates that India would have 40 million thalassemia carriers in 2020 or one in eight thalassemia carriers in India. Because traditional treatments and drugs have failed to effectively treat many ailments, people are now choosing advanced stem cell therapies instead, which should boost industry numbers. Demand is also anticipated to increase as a result of developments in stem cell therapies that hasten the healing process for cancer patients.
Restraints
Since stem cells are produced from human embryos, there are a number of ethical and safety concerns with their use. This limits the potential for human embryonic stem cell research (hESC). Furthermore, there is considerable debate around the generation of pluripotent stem cell lines from oocytes and embryos. The demand for stem cell therapies may be significantly impacted by medical hazards related to oocyte retrieval and various additional risks associated with experimental interventions.
Opportunities
Up to 2027, the end-use category for hospitals is anticipated to grow by almost 10.6%. The demand for stem cell therapies offered in hospitals to minimize difficulties brought on by intrusive approaches like surgical procedures is driving the industry's growth. The creation of novel stem cell therapies is currently being extensively researched by research labs and academic institutions that are linked with hospitals. Collaborations with research institutions enable hospitals to improve their treatment options, which in turn has a favorable impact on market statistics.
Type Insight
Depending on the kind, the allogeneic stem cell therapy market was responsible for around 58.5% of the total market in 2021. As the demand for allergic stem cells has increased in the past because of their application in the treatment of cancer, it is expected to increase in the next years due to the rising incidence of this terrible disease. Immune system cells, which can be obtained from a donor, can eliminate malignant cells with their assistance. Due to its rising use in treating various malignancies such as leukemia, lymphoma, and myeloma, the market is predicted to develop strongly in the upcoming years.
Application Insight
The region-related medication category is anticipated to have the greatest market share in the upcoming years, depending on the basis of application. The market share of the segment was approximately 91% in the past, and it is anticipated to rise strongly over the next several years. In the upcoming years, there will likely be an increase in demand for regenerative medicine, particularly for neurological problems, as there have been more approvals linked to clinical studies for treating various ailments. Governments from several countries are putting more money into the research and development of regenerative medicines. These drugs will be beneficial in the treatment of a variety of chronic illnesses, including diabetes, heart disease, and blood problems.
End User Insight
In terms of end users, the hospital sector is anticipated to hold a leading position in the ensuing years. Infrastructural equitability and a variety of treatment alternatives will aid in the market's expansion in the years to come. Due to their affiliation with various research institutes, which aid them in developing novel treatments for a variety of diseases, hospitals have been crucial in providing patients with high-quality care. These partnerships have been extremely beneficial for the market's growth in the past and will continue to be so in the future.
Related Reports
Healthcare Contract Manufacturing Market 2022 To 2030
https://www.precedenceresearch.com/healthcare-contract-manufacturing-market
Dermatology Devices Market 2022 To 2030
https://www.precedenceresearch.com/dermatology-devices-market
Healthcare Contract Research Outsourcing Market 2022 To 2030
https://www.precedenceresearch.com/healthcare-contract-research-outsourcing-market
Recent Development
- In March 2021, The U.S. FDA granted Novadip Biosciences' application for an Investigational New Drug (IND) for its NVD-003 autologous cell therapy product. Treatment for Congenital Pseudarthrosis of the Tibia is provided by the product (CPT). This tactic is probably going to improve their product line and widen their consumer base, increasing their market position.
- In January 2020, In order to produce cell-based medicines, Astellas Pharma Inc. entered into a licensing deal with Allele Biotechnology and Pharmaceuticals, Inc. Astellas' access to Allele's induced pluripotent stem cell (iPSC) technology for diverse cell therapies was to be increased as a result of this deal. This tactic allowed the organization to provide a cutting-edge product while also preserving its long-term client relationship.
Competitive Landscape
Astellas Pharma Inc., Novadip Biosciences, MEDIPOST, Fujifilm Cellular Dynamics, DiscGenics, Mesoblast Ltd., and Takeda Pharmaceutical are a few of the well-known companies in the stem cell therapy market. To promote business, companies use tactics including the development of novel products and mergers and acquisitions.
Market Segmentation
By Product
- Adult Stem Cells (ASCs)
- Hematopoietic
- Mesenchymal
- Neural
- Epithelial/Skin
- Others
- Human Embryonic Stem Cells (HESCs)
- Induced Pluripotent Stem Cells (iPSCs)
- Very Small Embryonic Like Stem Cells
By Therapy Type
- Autologous
- Allergenic
By Application
- Regenerative Medicine
- Neurology
- Orthopedics
- Oncology
- Hematology
- Cardiovascular and Myocardial Infraction
- Injuries
- Diabetes
- Liver Disorder
- Incontinence
- Others
- Drug Discovery and Development
By Technology
- Cell Acquiition
- Bone Marrow Harvest
- Umbilical Blood Cord
- Apheresis
- Cell Production
- Therapeutic Cloning
- In-vitro Fertilization
- Cell Culture
- Isolation
- Cryopreservation
- Expansion and Sub-Culture
By End User
- Hospitals
- Research institutes
- surgical institutes
- Orders
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
https://www.precedenceresearch.com/table-of-content/1989
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/1989
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333